 Michael Kahn
Concepts (426)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| beta Catenin | 17 | 2024 | 258 | 4.270 |
Why?
| | Electronic Health Records | 22 | 2024 | 1125 | 2.480 |
Why?
| | Wnt Signaling Pathway | 12 | 2024 | 202 | 2.100 |
Why?
| | Medical Informatics | 6 | 2017 | 99 | 1.630 |
Why?
| | Data Accuracy | 7 | 2024 | 63 | 1.540 |
Why?
| | Neoplastic Stem Cells | 8 | 2021 | 407 | 1.490 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2024 | 124 | 1.400 |
Why?
| | Medical Record Linkage | 9 | 2024 | 68 | 1.350 |
Why?
| | Biomedical Research | 9 | 2018 | 680 | 1.330 |
Why?
| | p300-CBP Transcription Factors | 3 | 2018 | 27 | 1.200 |
Why?
| | CREB-Binding Protein | 4 | 2018 | 33 | 1.180 |
Why?
| | Pediatrics | 5 | 2019 | 1097 | 1.160 |
Why?
| | Catenins | 2 | 2018 | 6 | 1.090 |
Why?
| | Crowding | 3 | 2011 | 37 | 1.040 |
Why?
| | Health Services Research | 3 | 2019 | 402 | 0.910 |
Why?
| | Pyrimidinones | 7 | 2018 | 122 | 0.860 |
Why?
| | Computer Communication Networks | 2 | 2014 | 32 | 0.860 |
Why?
| | Comparative Effectiveness Research | 5 | 2017 | 164 | 0.830 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 8 | 2018 | 252 | 0.830 |
Why?
| | Quality of Health Care | 4 | 2013 | 645 | 0.760 |
Why?
| | Imatinib Mesylate | 2 | 2024 | 79 | 0.750 |
Why?
| | Rare Diseases | 1 | 2023 | 111 | 0.750 |
Why?
| | Data Warehousing | 1 | 2022 | 5 | 0.750 |
Why?
| | Cloud Computing | 1 | 2022 | 7 | 0.750 |
Why?
| | Glioma | 2 | 2024 | 418 | 0.690 |
Why?
| | Patient-Centered Care | 3 | 2014 | 536 | 0.660 |
Why?
| | Information Storage and Retrieval | 5 | 2020 | 118 | 0.640 |
Why?
| | Clinical Trials as Topic | 5 | 2017 | 1031 | 0.620 |
Why?
| | Quality Assurance, Health Care | 3 | 2012 | 318 | 0.610 |
Why?
| | Machine Learning | 2 | 2023 | 554 | 0.560 |
Why?
| | Genomic Instability | 1 | 2018 | 57 | 0.550 |
Why?
| | Urology | 1 | 2018 | 61 | 0.540 |
Why?
| | gamma Catenin | 1 | 2017 | 13 | 0.530 |
Why?
| | Heterocyclic Compounds, 2-Ring | 1 | 2017 | 18 | 0.530 |
Why?
| | Child Health | 1 | 2019 | 153 | 0.520 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2017 | 143 | 0.500 |
Why?
| | Humans | 81 | 2025 | 140898 | 0.490 |
Why?
| | Hematopoiesis | 1 | 2017 | 193 | 0.480 |
Why?
| | Radiation Injuries | 1 | 2017 | 147 | 0.480 |
Why?
| | Medical Records Systems, Computerized | 4 | 2012 | 96 | 0.480 |
Why?
| | Data Mining | 2 | 2017 | 115 | 0.470 |
Why?
| | Databases, Factual | 6 | 2019 | 1441 | 0.460 |
Why?
| | Child Welfare | 2 | 2014 | 228 | 0.450 |
Why?
| | Evolution, Molecular | 1 | 2018 | 505 | 0.430 |
Why?
| | Forms and Records Control | 1 | 2013 | 20 | 0.420 |
Why?
| | Terminology as Topic | 2 | 2014 | 244 | 0.410 |
Why?
| | Community Networks | 1 | 2014 | 58 | 0.410 |
Why?
| | Quality Indicators, Health Care | 3 | 2013 | 304 | 0.390 |
Why?
| | Quality Improvement | 1 | 2021 | 1234 | 0.380 |
Why?
| | Population Surveillance | 3 | 2020 | 479 | 0.370 |
Why?
| | Cell Line, Tumor | 11 | 2024 | 3487 | 0.340 |
Why?
| | Nursing Assessment | 1 | 2011 | 57 | 0.340 |
Why?
| | Analgesia | 1 | 2011 | 102 | 0.340 |
Why?
| | Embryonic Stem Cells | 1 | 2011 | 129 | 0.330 |
Why?
| | Antineoplastic Agents | 4 | 2021 | 2156 | 0.330 |
Why?
| | Wearable Electronic Devices | 2 | 2021 | 55 | 0.330 |
Why?
| | MicroRNAs | 4 | 2021 | 691 | 0.320 |
Why?
| | Information Dissemination | 3 | 2019 | 209 | 0.310 |
Why?
| | Models, Statistical | 2 | 2019 | 667 | 0.310 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2010 | 80 | 0.310 |
Why?
| | Emergency Service, Hospital | 2 | 2011 | 2190 | 0.300 |
Why?
| | Pain | 2 | 2011 | 776 | 0.300 |
Why?
| | Child | 17 | 2020 | 22313 | 0.300 |
Why?
| | Accidental Falls | 1 | 2011 | 213 | 0.280 |
Why?
| | Luciferases | 2 | 2019 | 148 | 0.280 |
Why?
| | Mice | 15 | 2024 | 18057 | 0.280 |
Why?
| | United States | 18 | 2022 | 15195 | 0.280 |
Why?
| | Mass Screening | 2 | 2020 | 1300 | 0.280 |
Why?
| | Decision Support Systems, Clinical | 2 | 2023 | 263 | 0.280 |
Why?
| | Heart Defects, Congenital | 3 | 2020 | 879 | 0.270 |
Why?
| | Animals | 20 | 2024 | 37579 | 0.270 |
Why?
| | Algorithms | 5 | 2024 | 1763 | 0.260 |
Why?
| | Organizational Policy | 1 | 2007 | 76 | 0.260 |
Why?
| | Pregnenes | 1 | 2006 | 1 | 0.250 |
Why?
| | Fluorine | 1 | 2006 | 17 | 0.250 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2020 | 2524 | 0.250 |
Why?
| | Pain Management | 2 | 2025 | 395 | 0.240 |
Why?
| | Cell Differentiation | 3 | 2024 | 1999 | 0.240 |
Why?
| | Pain Clinics | 1 | 2025 | 4 | 0.240 |
Why?
| | Wnt Proteins | 4 | 2016 | 136 | 0.230 |
Why?
| | Transitional Care | 1 | 2025 | 44 | 0.220 |
Why?
| | Emergency Medical Services | 1 | 2011 | 650 | 0.220 |
Why?
| | Patient Care Team | 2 | 2025 | 664 | 0.220 |
Why?
| | Receptors, Glucocorticoid | 1 | 2006 | 137 | 0.220 |
Why?
| | Neoplasms | 2 | 2017 | 2718 | 0.210 |
Why?
| | Biological Science Disciplines | 1 | 2024 | 16 | 0.210 |
Why?
| | Knowledge Bases | 1 | 2024 | 27 | 0.210 |
Why?
| | Adolescent | 16 | 2022 | 22027 | 0.210 |
Why?
| | Diabetes Mellitus, Type 1 | 5 | 2020 | 3788 | 0.210 |
Why?
| | Pattern Recognition, Automated | 1 | 2024 | 74 | 0.210 |
Why?
| | Child, Preschool | 9 | 2020 | 11462 | 0.200 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 1 | 2024 | 52 | 0.200 |
Why?
| | Analgesics, Opioid | 3 | 2025 | 1114 | 0.200 |
Why?
| | Time Factors | 5 | 2025 | 6944 | 0.200 |
Why?
| | Phenotype | 3 | 2023 | 3172 | 0.190 |
Why?
| | Cell Movement | 5 | 2023 | 982 | 0.190 |
Why?
| | Adrenal Cortex Hormones | 1 | 2006 | 501 | 0.190 |
Why?
| | Data Collection | 3 | 2014 | 651 | 0.190 |
Why?
| | Tumor Microenvironment | 2 | 2024 | 699 | 0.190 |
Why?
| | Androgens | 1 | 2024 | 187 | 0.190 |
Why?
| | Pyrazoles | 1 | 2006 | 480 | 0.190 |
Why?
| | Mouth Neoplasms | 1 | 2023 | 89 | 0.190 |
Why?
| | Asthma | 3 | 2011 | 1919 | 0.180 |
Why?
| | Pyridines | 1 | 2006 | 553 | 0.180 |
Why?
| | Precision Medicine | 2 | 2024 | 433 | 0.180 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2022 | 166 | 0.180 |
Why?
| | Infant | 7 | 2020 | 9790 | 0.180 |
Why?
| | Life Cycle Stages | 1 | 2021 | 41 | 0.170 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2017 | 289 | 0.170 |
Why?
| | Hyaluronan Receptors | 2 | 2018 | 103 | 0.170 |
Why?
| | Reactive Oxygen Species | 1 | 2024 | 632 | 0.170 |
Why?
| | MDS1 and EVI1 Complex Locus Protein | 1 | 2020 | 8 | 0.170 |
Why?
| | Education, Distance | 1 | 2021 | 54 | 0.160 |
Why?
| | Recurrence | 1 | 2024 | 1104 | 0.160 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2022 | 353 | 0.160 |
Why?
| | Tumor Stem Cell Assay | 2 | 2018 | 34 | 0.160 |
Why?
| | Molecular Targeted Therapy | 3 | 2021 | 418 | 0.160 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2021 | 832 | 0.160 |
Why?
| | Chromatin | 1 | 2024 | 533 | 0.160 |
Why?
| | India | 4 | 2020 | 208 | 0.150 |
Why?
| | Colorado | 8 | 2024 | 4597 | 0.150 |
Why?
| | Information Services | 1 | 2019 | 45 | 0.150 |
Why?
| | Organ Transplantation | 1 | 2022 | 252 | 0.150 |
Why?
| | Information Management | 2 | 2012 | 17 | 0.150 |
Why?
| | Sentinel Surveillance | 2 | 2018 | 47 | 0.150 |
Why?
| | Immunotherapy | 1 | 2024 | 643 | 0.150 |
Why?
| | Young Adult | 8 | 2020 | 13646 | 0.150 |
Why?
| | Cell Proliferation | 5 | 2023 | 2497 | 0.150 |
Why?
| | Nerve Tissue Proteins | 1 | 2023 | 605 | 0.150 |
Why?
| | Penicillin Resistance | 1 | 1998 | 8 | 0.150 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2022 | 263 | 0.150 |
Why?
| | Cell Cycle Proteins | 1 | 2023 | 632 | 0.150 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2020 | 223 | 0.140 |
Why?
| | Acute Disease | 2 | 2011 | 1010 | 0.140 |
Why?
| | Metabolic Syndrome | 1 | 2022 | 348 | 0.140 |
Why?
| | Opioid-Related Disorders | 2 | 2025 | 562 | 0.140 |
Why?
| | Male | 17 | 2025 | 69893 | 0.140 |
Why?
| | Female | 19 | 2025 | 75540 | 0.140 |
Why?
| | Adult | 12 | 2025 | 39134 | 0.140 |
Why?
| | Reproducibility of Results | 4 | 2021 | 3336 | 0.140 |
Why?
| | Toxicity Tests | 1 | 2018 | 39 | 0.140 |
Why?
| | Colorectal Neoplasms | 2 | 2020 | 805 | 0.140 |
Why?
| | Cisplatin | 2 | 2021 | 326 | 0.140 |
Why?
| | Liver Neoplasms | 2 | 2022 | 740 | 0.130 |
Why?
| | Research Design | 4 | 2021 | 1104 | 0.130 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2024 | 1067 | 0.130 |
Why?
| | Pneumococcal Infections | 1 | 1998 | 108 | 0.130 |
Why?
| | Proto-Oncogene Proteins | 1 | 2021 | 624 | 0.130 |
Why?
| | Infant, Newborn | 5 | 2020 | 6257 | 0.130 |
Why?
| | Signal Transduction | 5 | 2015 | 5148 | 0.130 |
Why?
| | Datasets as Topic | 1 | 2017 | 123 | 0.130 |
Why?
| | Diabetic Ketoacidosis | 1 | 2020 | 209 | 0.130 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2017 | 126 | 0.130 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2017 | 132 | 0.130 |
Why?
| | Fractures, Bone | 2 | 2011 | 406 | 0.120 |
Why?
| | Epithelial-Mesenchymal Transition | 3 | 2015 | 210 | 0.120 |
Why?
| | Pain Measurement | 2 | 2025 | 552 | 0.120 |
Why?
| | E1A-Associated p300 Protein | 1 | 2016 | 12 | 0.120 |
Why?
| | Hospitals, University | 2 | 2011 | 175 | 0.120 |
Why?
| | Cross Infection | 1 | 1998 | 253 | 0.120 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2017 | 903 | 0.120 |
Why?
| | Vocabulary, Controlled | 2 | 2014 | 47 | 0.120 |
Why?
| | Adult Stem Cells | 1 | 2016 | 40 | 0.120 |
Why?
| | Logistic Models | 2 | 2011 | 2088 | 0.120 |
Why?
| | Cross-Sectional Studies | 3 | 2011 | 5645 | 0.120 |
Why?
| | Acute Kidney Injury | 1 | 2023 | 820 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2023 | 1430 | 0.110 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2015 | 68 | 0.110 |
Why?
| | Immunotherapy, Adoptive | 1 | 2019 | 359 | 0.110 |
Why?
| | Antigens, CD | 1 | 2018 | 544 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 433 | 0.110 |
Why?
| | Ovarian Neoplasms | 1 | 2021 | 580 | 0.110 |
Why?
| | Protein Kinase C | 1 | 2016 | 252 | 0.110 |
Why?
| | Receptors, Notch | 1 | 2015 | 87 | 0.110 |
Why?
| | Program Development | 2 | 2019 | 364 | 0.110 |
Why?
| | Renin-Angiotensin System | 1 | 2014 | 77 | 0.100 |
Why?
| | Hydronephrosis | 1 | 2014 | 36 | 0.100 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 532 | 0.100 |
Why?
| | Database Management Systems | 2 | 2012 | 51 | 0.100 |
Why?
| | Hematopoietic Stem Cells | 1 | 2017 | 411 | 0.100 |
Why?
| | Hedgehog Proteins | 1 | 2015 | 200 | 0.100 |
Why?
| | Organizational Innovation | 1 | 2014 | 128 | 0.100 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2015 | 175 | 0.100 |
Why?
| | Biomarkers, Tumor | 2 | 2018 | 1243 | 0.100 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2013 | 30 | 0.100 |
Why?
| | Interinstitutional Relations | 1 | 2013 | 49 | 0.100 |
Why?
| | Odds Ratio | 2 | 2011 | 1054 | 0.100 |
Why?
| | Chronic Disease | 1 | 2019 | 1811 | 0.100 |
Why?
| | Patient Identification Systems | 1 | 2013 | 16 | 0.100 |
Why?
| | Patient Handoff | 1 | 2013 | 38 | 0.100 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 250 | 0.100 |
Why?
| | Models, Theoretical | 2 | 2017 | 580 | 0.100 |
Why?
| | Cell Line | 5 | 2019 | 2879 | 0.100 |
Why?
| | Cells, Cultured | 2 | 2018 | 4199 | 0.100 |
Why?
| | Postoperative Period | 1 | 2013 | 360 | 0.090 |
Why?
| | Ethics Committees, Research | 1 | 2012 | 41 | 0.090 |
Why?
| | Multicenter Studies as Topic | 1 | 2013 | 362 | 0.090 |
Why?
| | TCF Transcription Factors | 1 | 2011 | 17 | 0.090 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2011 | 44 | 0.090 |
Why?
| | Retrospective Studies | 6 | 2022 | 16315 | 0.090 |
Why?
| | Risk Assessment | 2 | 2011 | 3484 | 0.090 |
Why?
| | Mice, Transgenic | 1 | 2017 | 2176 | 0.090 |
Why?
| | Documentation | 1 | 2013 | 193 | 0.090 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 1072 | 0.090 |
Why?
| | Operating Rooms | 1 | 2013 | 146 | 0.090 |
Why?
| | Registries | 4 | 2020 | 2143 | 0.090 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2011 | 50 | 0.090 |
Why?
| | Narcotics | 1 | 2011 | 54 | 0.090 |
Why?
| | Bed Occupancy | 1 | 2011 | 16 | 0.090 |
Why?
| | Research | 1 | 2014 | 431 | 0.090 |
Why?
| | Confidence Intervals | 1 | 2011 | 328 | 0.090 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2011 | 150 | 0.080 |
Why?
| | Protein Binding | 1 | 2017 | 2238 | 0.080 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2012 | 171 | 0.080 |
Why?
| | Heart Failure | 1 | 2023 | 2093 | 0.080 |
Why?
| | Joint Commission on Accreditation of Healthcare Organizations | 1 | 2010 | 9 | 0.080 |
Why?
| | Structure-Activity Relationship | 2 | 2014 | 576 | 0.080 |
Why?
| | Cell Lineage | 1 | 2011 | 351 | 0.080 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2012 | 270 | 0.080 |
Why?
| | Child, Hospitalized | 1 | 2010 | 53 | 0.080 |
Why?
| | Ambulatory Care | 1 | 2014 | 584 | 0.080 |
Why?
| | Injury Severity Score | 1 | 2011 | 560 | 0.080 |
Why?
| | Intubation, Intratracheal | 1 | 2012 | 288 | 0.080 |
Why?
| | Analgesics | 1 | 2011 | 225 | 0.080 |
Why?
| | Cooperative Behavior | 1 | 2012 | 455 | 0.080 |
Why?
| | Radiography | 1 | 2011 | 844 | 0.080 |
Why?
| | Patient Safety | 1 | 2013 | 334 | 0.070 |
Why?
| | Needs Assessment | 1 | 2011 | 384 | 0.070 |
Why?
| | RNA, Small Interfering | 3 | 2018 | 624 | 0.070 |
Why?
| | Estrogens | 1 | 2011 | 367 | 0.070 |
Why?
| | Workflow | 1 | 2010 | 175 | 0.070 |
Why?
| | Anti-Asthmatic Agents | 1 | 2011 | 273 | 0.070 |
Why?
| | Overweight | 1 | 2013 | 587 | 0.070 |
Why?
| | Age of Onset | 2 | 2020 | 533 | 0.070 |
Why?
| | Computational Biology | 3 | 2019 | 664 | 0.070 |
Why?
| | Pilot Projects | 1 | 2013 | 1815 | 0.070 |
Why?
| | Pulmonary Fibrosis | 1 | 2012 | 399 | 0.070 |
Why?
| | Gene Expression Regulation | 2 | 2014 | 2604 | 0.070 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1496 | 0.070 |
Why?
| | Intensive Care Units | 1 | 2013 | 869 | 0.070 |
Why?
| | Internet | 1 | 2012 | 682 | 0.060 |
Why?
| | Inpatients | 1 | 2011 | 512 | 0.060 |
Why?
| | Stereoisomerism | 1 | 2006 | 104 | 0.060 |
Why?
| | Microwaves | 1 | 2006 | 31 | 0.060 |
Why?
| | Pediatric Obesity | 1 | 2013 | 599 | 0.060 |
Why?
| | Down-Regulation | 2 | 2021 | 638 | 0.060 |
Why?
| | Mutation | 3 | 2022 | 3999 | 0.060 |
Why?
| | Brain Neoplasms | 1 | 2015 | 1275 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2012 | 1113 | 0.060 |
Why?
| | Ontario | 1 | 2025 | 95 | 0.060 |
Why?
| | Ambulatory Care Information Systems | 1 | 2005 | 5 | 0.060 |
Why?
| | Transcription, Genetic | 1 | 2011 | 1485 | 0.060 |
Why?
| | Indiana | 1 | 2024 | 34 | 0.060 |
Why?
| | Molecular Structure | 1 | 2006 | 501 | 0.060 |
Why?
| | Aqueous Humor | 2 | 1983 | 38 | 0.050 |
Why?
| | Positron-Emission Tomography | 1 | 2006 | 309 | 0.050 |
Why?
| | Patient Readmission | 1 | 2010 | 707 | 0.050 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 712 | 0.050 |
Why?
| | Hepatocyte Growth Factor | 1 | 2024 | 34 | 0.050 |
Why?
| | HEK293 Cells | 2 | 2018 | 737 | 0.050 |
Why?
| | Glycogen Storage Disease Type I | 1 | 2023 | 9 | 0.050 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2024 | 122 | 0.050 |
Why?
| | Ribosomal Proteins | 1 | 2024 | 92 | 0.050 |
Why?
| | Transcription Factors | 1 | 2011 | 1703 | 0.050 |
Why?
| | Mice, Nude | 2 | 2015 | 689 | 0.050 |
Why?
| | Healthcare Disparities | 1 | 2010 | 671 | 0.050 |
Why?
| | Androgen Antagonists | 1 | 2024 | 92 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2024 | 99 | 0.050 |
Why?
| | Hospitals, General | 1 | 2022 | 23 | 0.050 |
Why?
| | Trabecular Meshwork | 1 | 1983 | 79 | 0.050 |
Why?
| | Receptors, Androgen | 1 | 2024 | 153 | 0.050 |
Why?
| | Exercise | 1 | 2014 | 2108 | 0.050 |
Why?
| | Kinetics | 1 | 2006 | 1651 | 0.050 |
Why?
| | Prevalence | 2 | 2019 | 2780 | 0.050 |
Why?
| | Health Insurance Portability and Accountability Act | 1 | 2022 | 13 | 0.050 |
Why?
| | Bronchial Diseases | 1 | 2002 | 37 | 0.050 |
Why?
| | Middle Aged | 5 | 2025 | 34487 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2010 | 1020 | 0.050 |
Why?
| | Serine Proteinase Inhibitors | 1 | 2002 | 48 | 0.050 |
Why?
| | Glucocorticoids | 1 | 2006 | 533 | 0.040 |
Why?
| | Glutathione | 1 | 1983 | 362 | 0.040 |
Why?
| | Immune Evasion | 1 | 2022 | 63 | 0.040 |
Why?
| | Hepatitis B | 1 | 2022 | 67 | 0.040 |
Why?
| | Serine Endopeptidases | 1 | 2002 | 126 | 0.040 |
Why?
| | Fitness Trackers | 1 | 2021 | 15 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2006 | 1968 | 0.040 |
Why?
| | Appointments and Schedules | 1 | 2002 | 96 | 0.040 |
Why?
| | Collagen | 1 | 2023 | 460 | 0.040 |
Why?
| | Fibrosis | 1 | 2023 | 542 | 0.040 |
Why?
| | Promoter Regions, Genetic | 2 | 2016 | 1241 | 0.040 |
Why?
| | Insurance Claim Reporting | 1 | 2020 | 26 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2002 | 271 | 0.040 |
Why?
| | Piperidines | 1 | 2002 | 217 | 0.040 |
Why?
| | Microsatellite Repeats | 1 | 2020 | 159 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2021 | 309 | 0.040 |
Why?
| | 3' Untranslated Regions | 1 | 2020 | 149 | 0.040 |
Why?
| | Prospective Studies | 3 | 2020 | 7749 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2011 | 2235 | 0.040 |
Why?
| | Probability | 1 | 2020 | 308 | 0.040 |
Why?
| | Receptors, Antigen | 1 | 2019 | 17 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 956 | 0.040 |
Why?
| | Demography | 1 | 2020 | 295 | 0.040 |
Why?
| | Bias | 1 | 2020 | 208 | 0.040 |
Why?
| | Missouri | 1 | 1998 | 60 | 0.040 |
Why?
| | Gene Expression | 2 | 2016 | 1490 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 810 | 0.040 |
Why?
| | Cohort Studies | 2 | 2022 | 5789 | 0.040 |
Why?
| | Consumer Product Safety | 1 | 2018 | 30 | 0.030 |
Why?
| | Computer Systems | 1 | 2018 | 51 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 5931 | 0.030 |
Why?
| | Artificial Intelligence | 1 | 2002 | 332 | 0.030 |
Why?
| | Linear Models | 1 | 2019 | 854 | 0.030 |
Why?
| | Prognosis | 2 | 2020 | 4060 | 0.030 |
Why?
| | Lymphocytes | 1 | 2019 | 394 | 0.030 |
Why?
| | Mice, Knockout | 2 | 2016 | 3064 | 0.030 |
Why?
| | Mice, Inbred BALB C | 2 | 2014 | 1271 | 0.030 |
Why?
| | Aquaporin 5 | 1 | 2016 | 3 | 0.030 |
Why?
| | Community-Acquired Infections | 1 | 1998 | 176 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2019 | 672 | 0.030 |
Why?
| | Wnt-5a Protein | 1 | 2016 | 25 | 0.030 |
Why?
| | Electric Impedance | 1 | 2016 | 112 | 0.030 |
Why?
| | Students | 1 | 2021 | 645 | 0.030 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2015 | 20 | 0.030 |
Why?
| | Alveolar Epithelial Cells | 1 | 2016 | 116 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 2062 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1195 | 0.030 |
Why?
| | Ubiquitination | 1 | 2015 | 107 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2015 | 193 | 0.030 |
Why?
| | Health Planning Guidelines | 1 | 2014 | 24 | 0.030 |
Why?
| | SOXB1 Transcription Factors | 1 | 2015 | 65 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2019 | 719 | 0.030 |
Why?
| | Inhibitory Concentration 50 | 1 | 2014 | 91 | 0.030 |
Why?
| | Drug Synergism | 1 | 2015 | 369 | 0.030 |
Why?
| | Herpesvirus 4, Human | 1 | 2015 | 165 | 0.030 |
Why?
| | Drug Design | 1 | 2015 | 168 | 0.030 |
Why?
| | Calibration | 1 | 2014 | 152 | 0.030 |
Why?
| | Proteinuria | 1 | 2014 | 99 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2015 | 323 | 0.030 |
Why?
| | Semantics | 1 | 2014 | 97 | 0.030 |
Why?
| | Albumins | 1 | 2014 | 114 | 0.030 |
Why?
| | Podocytes | 1 | 2014 | 68 | 0.030 |
Why?
| | Kidney Tubules | 1 | 2014 | 116 | 0.030 |
Why?
| | ras Proteins | 1 | 2014 | 145 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1643 | 0.030 |
Why?
| | RNA Interference | 1 | 2015 | 468 | 0.020 |
Why?
| | Incidence | 1 | 2020 | 2782 | 0.020 |
Why?
| | Carcinoma | 1 | 2015 | 230 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2016 | 463 | 0.020 |
Why?
| | Drug Discovery | 1 | 2014 | 146 | 0.020 |
Why?
| | Names | 1 | 2013 | 14 | 0.020 |
Why?
| | Systems Integration | 1 | 2013 | 38 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2014 | 5194 | 0.020 |
Why?
| | Tumor Suppressor Proteins | 1 | 2015 | 325 | 0.020 |
Why?
| | Aged | 2 | 2025 | 24666 | 0.020 |
Why?
| | Quality Control | 1 | 2013 | 162 | 0.020 |
Why?
| | Airway Extubation | 1 | 2013 | 60 | 0.020 |
Why?
| | Research Personnel | 1 | 2014 | 177 | 0.020 |
Why?
| | Creatinine | 1 | 2014 | 490 | 0.020 |
Why?
| | Ligands | 1 | 2014 | 667 | 0.020 |
Why?
| | Snail Family Transcription Factors | 1 | 2011 | 18 | 0.020 |
Why?
| | Smad3 Protein | 1 | 2012 | 44 | 0.020 |
Why?
| | Medical Errors | 1 | 2013 | 119 | 0.020 |
Why?
| | Phosphorylation | 1 | 2016 | 1758 | 0.020 |
Why?
| | Gene Targeting | 1 | 2011 | 83 | 0.020 |
Why?
| | Oxygen Consumption | 1 | 2014 | 714 | 0.020 |
Why?
| | Binding Sites | 1 | 2014 | 1315 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2018 | 2822 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2011 | 131 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 3005 | 0.020 |
Why?
| | Oligonucleotides | 1 | 2011 | 147 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2019 | 2003 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2013 | 527 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2920 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2014 | 1022 | 0.020 |
Why?
| | Zebrafish | 1 | 2014 | 504 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2011 | 599 | 0.020 |
Why?
| | Actins | 1 | 2012 | 423 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2011 | 674 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2011 | 498 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2013 | 685 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1240 | 0.020 |
Why?
| | Repressor Proteins | 1 | 2011 | 428 | 0.020 |
Why?
| | Rats | 1 | 2016 | 5594 | 0.020 |
Why?
| | Kidney | 1 | 2014 | 1475 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1786 | 0.010 |
Why?
| | Practice Guidelines as Topic | 1 | 2013 | 1536 | 0.010 |
Why?
| | Information Centers | 1 | 2005 | 3 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2020 | 11125 | 0.010 |
Why?
| | Hospitals | 1 | 2010 | 694 | 0.010 |
Why?
| | Databases as Topic | 1 | 2005 | 68 | 0.010 |
Why?
| | Body Mass Index | 1 | 2013 | 2374 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2011 | 1761 | 0.010 |
Why?
| | Diamide | 1 | 1983 | 5 | 0.010 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1328 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2014 | 4407 | 0.010 |
Why?
| | Iodoacetates | 1 | 1983 | 3 | 0.010 |
Why?
| | Iodoacetamide | 1 | 1983 | 5 | 0.010 |
Why?
| | Ethylmaleimide | 1 | 1983 | 18 | 0.010 |
Why?
| | Carmustine | 1 | 1983 | 51 | 0.010 |
Why?
| | Sulfhydryl Reagents | 1 | 1983 | 12 | 0.010 |
Why?
| | Anterior Chamber | 1 | 1983 | 26 | 0.010 |
Why?
| | Free Radicals | 1 | 1983 | 114 | 0.010 |
Why?
| | Biomarkers | 1 | 2014 | 4175 | 0.010 |
Why?
| | Tryptases | 1 | 2002 | 13 | 0.010 |
Why?
| | Rabbits | 1 | 1983 | 754 | 0.010 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2002 | 41 | 0.010 |
Why?
| | Pulmonary Eosinophilia | 1 | 2002 | 27 | 0.010 |
Why?
| | Lens, Crystalline | 1 | 1983 | 133 | 0.010 |
Why?
| | Hydrogen Peroxide | 1 | 1983 | 338 | 0.010 |
Why?
| | Time | 1 | 2002 | 87 | 0.010 |
Why?
| | Pulmonary Edema | 1 | 2002 | 114 | 0.010 |
Why?
| | Ovalbumin | 1 | 2002 | 196 | 0.010 |
Why?
| | Bronchial Hyperreactivity | 1 | 2002 | 104 | 0.010 |
Why?
| | Mucus | 1 | 2002 | 78 | 0.010 |
Why?
| | Cattle | 1 | 1983 | 991 | 0.010 |
Why?
| | Amino Acids | 1 | 1983 | 493 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 1983 | 1086 | 0.010 |
Why?
| | Eosinophils | 1 | 2002 | 325 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2002 | 649 | 0.010 |
Why?
| | Glucose | 1 | 1983 | 1031 | 0.010 |
Why?
| | Risk Factors | 1 | 2012 | 10430 | 0.010 |
Why?
| | Decision Support Techniques | 1 | 2002 | 429 | 0.010 |
Why?
| | Models, Molecular | 1 | 2002 | 1602 | 0.010 |
Why?
| | Cytokines | 1 | 2002 | 2092 | 0.010 |
Why?
| | Inflammation | 1 | 2002 | 2891 | 0.010 |
Why?
| | Lung | 1 | 2002 | 4127 | 0.000 |
Why?
|
|
Kahn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|